Basilea berichtet über Interim-Ergebnisse aus Phase-1/2-Studie FIDES-02, in der Derazantinib bei Patienten mit fortgeschrittenem Urothelkarzinom erprobt wird

by NASDAQ Market News October 13, 2020

NASDAQ Market News
Click here to email author

Global X-Ray Detectors Industry

Dupixent® (dupilumab) significantly reduced severe asthma attacks in children and is the only biologic to demonstrate improvement in children’s lung function in a randomized Phase 3 trial

Ads